We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search

Clear all

Refine your search

Content type

Tags

Firm name

Author

Language

437 results found

Article

Winston & Strawn LLP | USA | 20 Dec 2018

Roche Molecular Systems, Inc. v. Cepheid, No. 2017-1690 (Fed. Cir. Oct. 9, 2018)

The Federal Circuit affirmed the Northern District of California’s summary judgment finding that patent claims related to detecting Mycobacterium

Article

Bradley Arant Boult Cummings LLP | USA | 29 Oct 2018

Rules for Patenting Genetic Biomarkers Are Updated in Roche v. Cepeid

As the readers of this blog are no doubt aware, patenting DNA defined only by a naturally occurring nucleotide sequence was banned by the U.S. Supreme

Article

Banner Witcoff | USA | 31 May 2018

Can Challengers Now Attack Subject Matter Eligibility in Inter Partes Reviews?

The statute authorizing inter partes reviews (IPR) explicitly limits the grounds for cancellation to Sections 102 and 103 of the patent statute:

Article

Knobbe Martens | USA | 4 Apr 2018

23andMe Wins FDA Approval for Test to Detect BRCA Mutations

The U.S. Food and Drug Administration (FDA) recently authorized 23andMe to market its Personal Genome Service Genetic Health Risk Report for

Article

Blake Cassels & Graydon LLP | Canada | 27 Oct 2016

Breveter le vivant : une question qui gène

Si la Cour suprême du Canada (CSC) a déjà commenté l’épineuse question de savoir si les gènes peuvent être brevetés, aucun tribunal canadien n’a

Article

DLA Piper | Australia | 29 Jul 2016

Australian Patent Office resolves a Myriad of uncertainties

In D'Arcy v Myriad Genetics Inc 2015 HCA 35 (D'Arcy v Myriad), the High Court of Australia unanimously held that the impugned claims of Myriad's

Article

DLA Piper | USA | 26 Jul 2016

FDA’s new Next Generation Sequencing Draft Guidance leaves fundamental questions unanswered: key points

The Food and Drug Administration has released a 25-page Draft Guidance document addressing FDA oversight of certain applications of Next Generation

Article

Foley & Lardner LLP | USA | 7 Jul 2016

CAFC Finds Cryopreservation Method Patent Eligible

The Federal Circuit ruled that the cryopreservation methods at issue in Rapid Litigation Mgmt. Ltd. v. CellzDirect Inc., are patent eligible under 35

Article

Foley & Lardner LLP | USA | 11 Apr 2016

Methods Exploiting Junk DNA May Be Useful But Lack Patent Eligibility

Striking another blow against patent eligibility in the field of biotechnology, the Federal Circuit agreed with the district court that methods that

Article

ENSafrica | Australia | 6 Nov 2015

Patentability of genetic material

The patentability of genetic material has again come into the spotlight with the recent high court decision in Australia in the Myriad Genetics Inc

Previous page 1 2 3 ...